Literature DB >> 26729432

Importance of Radiation Oncologist Experience Among Patients With Head-and-Neck Cancer Treated With Intensity-Modulated Radiation Therapy.

Isabel J Boero1, Anthony J Paravati1, Beibei Xu1, Ezra E W Cohen1, Loren K Mell1, Quynh-Thu Le1, James D Murphy2.   

Abstract

PURPOSE: Over the past decade, intensity-modulated radiation therapy (IMRT) has replaced conventional radiation techniques in the management of head-and-neck cancers (HNCs). We conducted this population-based study to evaluate the influence of radiation oncologist experience on outcomes in patients with HNC treated with IMRT compared with patients with HNC treated with conventional radiation therapy.
METHODS: We identified radiation providers from Medicare claims of 6,212 Medicare beneficiaries with HNC treated between 2000 and 2009. We analyzed the impact of provider volume on all-cause mortality, HNC mortality, and toxicity end points after treatment with either conventional radiation therapy or IMRT. All analyses were performed by using either multivariable Cox proportional hazards or Fine-Gray regression models controlling for potential confounding variables.
RESULTS: Among patients treated with conventional radiation, we found no significant relationship between provider volume and patient survival or any toxicity end point. Among patients receiving IMRT, those treated by higher-volume radiation oncologists had improved survival compared with those treated by low-volume providers. The risk of all-cause mortality decreased by 21% for every additional five patients treated per provider per year (hazard ratio [HR], 0.79; 95% CI, 0.67 to 0.94). Patients treated with IMRT by higher-volume providers had decreased HNC-specific mortality (subdistribution HR, 0.68; 95% CI, 0.50 to 0.91) and decreased risk of aspiration pneumonia (subdistribution HR, 0.72; 95% CI, 0.52 to 0.99).
CONCLUSION: Patients receiving IMRT for HNC had improved outcomes when treated by higher-volume providers. These findings will better inform patients and providers when making decisions about treatment, and emphasize the critical importance of high-quality radiation therapy for optimal treatment of HNC.
© 2016 by American Society of Clinical Oncology.

Entities:  

Mesh:

Year:  2016        PMID: 26729432      PMCID: PMC4872027          DOI: 10.1200/JCO.2015.63.9898

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  22 in total

1.  Experience-based quality control of clinical intensity-modulated radiotherapy planning.

Authors:  Kevin L Moore; R Scott Brame; Daniel A Low; Sasa Mutic
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-01-27       Impact factor: 7.038

2.  Predictors of IMRT and conformal radiotherapy use in head and neck squamous cell carcinoma: a SEER-Medicare analysis.

Authors:  David J Sher; Bridget A Neville; Aileen B Chen; Deborah Schrag
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-05-17       Impact factor: 7.038

3.  Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection.

Authors:  Deborah Schrag; Katherine S Panageas; Elyn Riedel; Laura D Cramer; Jose G Guillem; Peter B Bach; Colin B Begg
Journal:  Ann Surg       Date:  2002-11       Impact factor: 12.969

4.  The influence of hospital volume on survival after resection for lung cancer.

Authors:  P B Bach; L D Cramer; D Schrag; R J Downey; S E Gelfand; C B Begg
Journal:  N Engl J Med       Date:  2001-07-19       Impact factor: 91.245

5.  Associations between hospital and surgeon procedure volumes and patient outcomes after ovarian cancer resection.

Authors:  Deborah Schrag; Craig Earle; Feng Xu; Katherine S Panageas; K Robin Yabroff; Robert E Bristow; Edward L Trimble; Joan L Warren
Journal:  J Natl Cancer Inst       Date:  2006-02-01       Impact factor: 13.506

6.  Variations in morbidity after radical prostatectomy.

Authors:  Colin B Begg; Elyn R Riedel; Peter B Bach; Michael W Kattan; Deborah Schrag; Joan L Warren; Peter T Scardino
Journal:  N Engl J Med       Date:  2002-04-11       Impact factor: 91.245

7.  Institutional clinical trial accrual volume and survival of patients with head and neck cancer.

Authors:  Evan J Wuthrick; Qiang Zhang; Mitchell Machtay; David I Rosenthal; Phuc Felix Nguyen-Tan; André Fortin; Craig L Silverman; Adam Raben; Harold E Kim; Eric M Horwitz; Nancy E Read; Jonathan Harris; Qian Wu; Quynh-Thu Le; Maura L Gillison
Journal:  J Clin Oncol       Date:  2014-12-08       Impact factor: 44.544

8.  Completion of radiotherapy for local and regional head and neck cancer in medicare.

Authors:  Megan Dann Fesinmeyer; Vivek Mehta; Lauri Tock; David Blough; Cara McDermott; Scott D Ramsey
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2009-09

9.  Impact of hospital volume on operative mortality for major cancer surgery.

Authors:  C B Begg; L D Cramer; W J Hoskins; M F Brennan
Journal:  JAMA       Date:  1998-11-25       Impact factor: 56.272

10.  Clinical evaluation of multi-atlas based segmentation of lymph node regions in head and neck and prostate cancer patients.

Authors:  Carl Sjöberg; Martin Lundmark; Christoffer Granberg; Silvia Johansson; Anders Ahnesjö; Anders Montelius
Journal:  Radiat Oncol       Date:  2013-10-03       Impact factor: 3.481

View more
  42 in total

1.  Nomogram to Predict the Benefit of Intensive Treatment for Locoregionally Advanced Head and Neck Cancer.

Authors:  Loren K Mell; Hanjie Shen; Phuc Felix Nguyen-Tân; David I Rosenthal; Kaveh Zakeri; Lucas K Vitzthum; Steven J Frank; Peter B Schiff; Andy M Trotti; James A Bonner; Christopher U Jones; Sue S Yom; Wade L Thorstad; Stuart J Wong; George Shenouda; John A Ridge; Qiang E Zhang; Quynh-Thu Le
Journal:  Clin Cancer Res       Date:  2019-08-16       Impact factor: 12.531

2.  Survival Rates Using Individualized Bioselection Treatment Methods in Patients With Advanced Laryngeal Cancer.

Authors:  Gregory T Wolf; Emily Bellile; Avraham Eisbruch; Susan Urba; Carol R Bradford; Lisa Peterson; Mark E Prince; Theodoros N Teknos; Douglas B Chepeha; Norman D Hogikyan; Scott A McLean; Jeffery Moyer; Jeremy M G Taylor; Francis P Worden
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-04-01       Impact factor: 6.223

3.  Radiation therapy treatment facility and overall survival in the adjuvant setting for locally advanced head and neck squamous cell carcinoma.

Authors:  Nicholas C J Lee; Jacqueline R Kelly; Yi An; Henry S Park; Benjamin L Judson; Barbara A Burtness; Zain A Husain
Journal:  Cancer       Date:  2019-02-12       Impact factor: 6.860

4.  Simulation as More Than a Treatment-Planning Tool: A Systematic Review of the Literature on Radiation Oncology Simulation-Based Medical Education.

Authors:  Michael K Rooney; Fan Zhu; Erin F Gillespie; Jillian R Gunther; Ryan P McKillip; Matthew Lineberry; Ara Tekian; Daniel W Golden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-06-06       Impact factor: 7.038

5.  The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era.

Authors:  Zachary S Zumsteg; Benjamin H Lok; Allen S Ho; Esther Drill; Zhigang Zhang; Nadeem Riaz; Stephen L Shiao; Jennifer Ma; Sean M McBride; C Jillian Tsai; Shrujal S Baxi; Eric J Sherman; Nancy Y Lee
Journal:  Cancer       Date:  2016-12-16       Impact factor: 6.860

6.  Postoperative radiation performed at the same surgical facility associated with improved overall survival in oral cavity squamous cell carcinoma.

Authors:  Arya Amini; William A Stokes; Bernard L Jones; Sagus Sampath; Robert S Kang; Thomas J Gernon; Ellie G Maghami; Erminia Massarelli; Cathy J Bradley; Sana D Karam
Journal:  Head Neck       Date:  2019-02-09       Impact factor: 3.147

7.  [IMRT experience of radiation oncologists and prognosis in head-and-neck cancer].

Authors:  Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2016-06       Impact factor: 3.621

8.  Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting.

Authors:  Wassim Kassouf; Armen Aprikian; Fred Saad; Rodney H Breau; Girish Kulkarni; David M Guttman; Ken Bagshaw; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Fadi Brimo; Peter Chung; Darrel Drachenberg; Yves Fradet; Niels Jacobsen; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Alex Zlotta; Neil Fleshner; D Robert Siemens; Peter C Black
Journal:  Can Urol Assoc J       Date:  2018-03-19       Impact factor: 1.862

9.  Association between hospital volume and receipt of treatment and survival in patients with glioblastoma.

Authors:  Matthew Koshy; David J Sher; Michael Spiotto; Zain Husain; Herb Engelhard; Konstantin Slavin; Martin K Nicholas; Ralph R Weichselbaum; Chad Rusthoven
Journal:  J Neurooncol       Date:  2017-08-23       Impact factor: 4.130

10.  Development of a novel salivary gland cancer lymph node staging system.

Authors:  Katri Aro; Allen S Ho; Michael Luu; Sungjin Kim; Mourad Tighiouart; Jon Mallen-St Clair; Emi J Yoshida; Stephen L Shiao; Ilmo Leivo; Zachary S Zumsteg
Journal:  Cancer       Date:  2018-05-09       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.